Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2017
At a glance
- Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 02 Sep 2016 Planned End Date changed from 1 Aug 2019 to 1 Sep 2019.
- 02 Sep 2016 Planned primary completion date changed from 1 Aug 2018 to 1 Sep 2018.
- 02 Sep 2016 Status changed from not yet recruiting to recruiting.